Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals on June 16, 2026.
1 report, 1 independent
Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup downgraded the stock rating and target price for Catalyst Pharmaceuticals on June 16, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Catalyst Pharmaceuticals
company in Coral Gables, United States
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
Related events
- Citigroup and Jefferies Financial Group raised their price targets and issued buy ratings for Beauty.
- Citigroup maintained a market outperform rating for Ethos Technologies Inc. on November 6, 2026.
- Citigroup decreased its target price for RELX on July 25, 2026.
- Citigroup upgraded its target price and gave a buy rating for Fortrea.
- Bank of America updated its price objective and rating, while Citigroup reissued a neutral rating on Biogen shares.